BD Holdings, Inc is a cutting-edge healthcare company based in Coralville, IA, specializing in precision cancer screenings and diagnostic tools for addiction and disease. Their patented epigenetics tests and artificial intelligence technology provide personalized guidance for early cancer detection, quantification of smoking intensity, and monitoring of problem drinking. With a deep pipeline of innovative products, BD Holdings aims to enhance personal, professional, and family well-being by revolutionizing cancer care through early detection and prevention strategies.
Backed by internationally known researchers funded by the National Institutes of Health, BD Holdings is committed to advancing personalized precision healthcare. Their tests are available to patients, healthcare providers, and insurers, offering accurate risk assessments for underwriting, detection of potential substance abuse in the workplace, and a whole new way for individuals to monitor their health and discover insights about their genes. With a simple and thorough process, BD Holdings empowers individuals to make positive changes to their consumption and track their progress, ultimately leading to a healthier lifestyle and reduced disease risk.
Generated from the website